Results 201 to 210 of about 48,812 (228)

Ipilimumab

Reactions Weekly, 2016
  +6 more sources

Ipilimumab

Drugs, 2011
Ipilimumab (Yervoy®) is an anti-cytotoxic T-lymphocyte antigen (CTLA)-4 monoclonal antibody that has been approved in the US for the first- or second-line treatment of patients with malignant melanoma. In the EU, it is awaiting approval as second-line therapy for melanoma. Ipilimumab blocks the effects of the negative T-cell regulator CTLA-4, which may
Fiona, Cameron, Glenn, Whiteside, Caroline, Perry   +2 more
openaire   +2 more sources

Ipilimumab

Reactions Weekly, 2013
  +6 more sources

Ipilimumab

Reactions Weekly, 2015
  +7 more sources

Ipilimumab/ipilimumab/nivolumab

Reactions Weekly, 2022
openaire   +1 more source

Ipilimumab

Reactions Weekly, 2012
Wörmann, Bernhard, Mackensen, Andreas, Deutsche Krebsgesellschaft. Arbeitsgemeinschaft Für Internistische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, Brossart, Peter, Keilholz, Ulrich, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie. Arbeitsgemeinschaft Für Internistische Onkologie   +6 more
  +5 more sources

Ipilimumab

Reactions Weekly, 2014
openaire   +2 more sources

Ipilimumab

Reactions Weekly, 2023
openaire   +2 more sources

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

Annals of Oncology, 2022
Charlotte Robert, Georgina V. Long, Jean-Jacques Grob   +2 more
exaly  

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Annals of Oncology, 2017
Charlotte Robert, Emilie Lanoy, Patricia Lepage   +2 more
exaly